Seattle Genetics Inc (SGEN) 44.90 $SGEN Technical

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 9:05 AM

Seattle Genetics Inc (SGEN) 44.90 $SGEN

Technical Roundup on Biotech Stocks -- Keryx Biopharma, Inovio Pharma, Seattle Genetics, and Arrowhead Pharma
PR Newswire - Tue Aug 30, 7:15AM CDT
The Biotech arena includes companies that use biological processes to develop technological solutions, and manufacture products intended to improve the quality of life. Stocks under assessment on Stock-Callers.com today are: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Inovio Pharmaceuticals Inc. (NASDAQ: INO), Seattle Genetics Inc. (NASDAQ: SGEN), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). Sign up today and download for free the research reports for the stocks covered today at:
INO: 9.14 (-0.03), ARWR: 7.06 (+0.13), SGEN: 44.90 (+0.35), KERX: 4.13 (+0.03)

Seattle Genetics Set to Possibly Pullback After Yesterday's Rally of 2.84%
Comtex SmarTrend(R) - Mon Aug 22, 4:01PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $45.42 to a high of $47.01. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $46.50 on volume of 305,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 44.90 (+0.35)

Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS(R) (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
BusinessWire - Mon Aug 01, 5:59AM CDT
---Abstract to be Submitted to ASH for Presentation at the 2016 Annual Meeting-
SGEN: 44.90 (+0.35)

Learn how to target a 13% return on Under Armour, or get option-trade ideas on SPDR Gold Trust, Seattle Genetics, Priceline and Lockheed Martin Corporation or any stock you choose
PR Newswire - Thu Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GLD, LMT, PCLN, SGEN, and UA.
UA: 39.70 (-0.05), LMT: 244.00 (+0.39), SGEN: 44.90 (+0.35), GLD: 126.72 (+1.43), PCLN: 1,418.59 (+1.86)

Downgrade Alert for Seattle Genetics (SGEN)
Comtex SmarTrend(R) - Thu Jul 28, 3:49AM CDT
Seattle Genetics (NASDAQ:SGEN) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $47.98 on volume of 1.4 million shares, above average daily volume of 954,000. There is potential upside of 3.6% for shares of Seattle Genetics based on a current price of $47.98 and an average consensus analyst price target of $49.69. The stock should find initial support at its 200-day moving average (MA) of $39.22 and further support at its 50-day MA of $35.07.
SGEN: 44.90 (+0.35)

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
PR Newswire - Sat Jun 11, 1:30AM CDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in frontline patients with acute myeloid leukemia (AML) who had declined intensive therapy. 33A is an investigational antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. CD33 is expressed on leukemic blasts in nearly all AML patients with expression generally consistent regardless of age, cytogenetic abnormalities or underlying mutations.
SGEN: 44.90 (+0.35)

Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
BusinessWire - Mon Jun 06, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TOKYO:4503) today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016, in Chicago, IL.
SGEN: 44.90 (+0.35)

Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
PR Newswire - Mon Jun 06, 7:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Seattle Genetics, Inc. (NASDAQ: SGEN) today presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.
SGEN: 44.90 (+0.35)

Seattle Genetics Rises 5.91% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:37PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $40.40 to a high of $43.37. Yesterday, the shares gained 5.9%, which took the trading range above the 3-day high of $41.14 on volume of 663,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 44.90 (+0.35)

Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:59PM CDT
Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN-CD33A).
ABT: 42.30 (+0.28), JNJ: 120.27 (+1.19), SGEN: 44.90 (+0.35), SNY: 39.20 (+0.79)

Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
BusinessWire - Wed May 25, 7:00AM CDT
---Data Presented at the 2015 American Society of Hematology Annual Meeting Demonstrated Encouraging Anti-leukemic Activity and Support Advancing 33A into a Registrational Trial-
SGEN: 44.90 (+0.35)

What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech
PR Newswire - Wed May 18, 7:38AM CDT
The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and trading alerts at:
SGEN: 44.90 (+0.35), OPHT: 52.97 (+0.16), THLD: 1.05 (-0.02), CHMA: 2.46 (-0.01)

Taking Inventory on Seattle Genetics, Inc. Earnings
Brian Orelli, The Motley Fool - Motley Fool - Wed May 04, 5:04PM CDT
Seattle Genetics released first-quarter earnings results on Thursday, and while sales of Adcetris continued to grow, they weren't quite as robust as investors were hoping for. Seattle Genetics results: The raw numbers ...
SGEN: 44.90 (+0.35)

Seattle Genetics to Present at Upcoming Investor Conferences
BusinessWire - Wed May 04, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section.
SGEN: 44.90 (+0.35)

Seattle Genetics (SGEN) Posts Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 1:09PM CDT
Seattle Genetics (SGEN) reported a loss of 15 cents per share, wider than the Zacks Consensus Estimate of a loss of 11 cents.
EBS: 26.41 (-0.24), SGEN: 44.90 (+0.35), AEGR: 1.59 (-0.04)

Seattle Genetics reports 1Q loss
Automated Insights - Thu Apr 28, 4:59PM CDT
BOTHELL, Wash. (AP) _ Seattle Genetics Inc. (SGEN) on Thursday reported a loss of $20.5 million in its first quarter.
SGEN: 44.90 (+0.35)

Seattle Genetics Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:02PM CDT
---Top-Line Data from ADCETRIS Phase 3 ALCANZA Trial Expected in Third Quarter of 2016-
SGEN: 44.90 (+0.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

China, Europe, Africa Team Up for Green Energy Push

The Need for Unity in a Warming World Some folks out there might be scratching their heads, wondering what sparks are flying between China, Europe, and Africa this time. Well, during the 2026 China-Europe-Africa Green Energy Development Forum held in sunny Zhejiang, the theme was loud and clear: We've got to deepen green partnerships to build a zero-carbon future. They're...

Deadline Looms for BETR Investors: Take Action Now

What’s the Fuss About? Alright folks, let’s lay this out simple: Better Home & Finance Holding Company (NASDAQ: BETR) is in hot water. A class action’s been slapped on them, accusing the firm of sugarcoating its business prospects. If you bought BETR shares between March 13, 2026, and May 7, 2026, you might have a dog in this fight. Buckle up, because the stakes are...

NSAP's First Board Aims to Revolutionize Autism Care

Out in Silicon Valley, where innovation isn’t just a buzzword, the National Society of Autism Professionals (NSAP) is stirring the pot with some serious leadership moves. Just this month, they cobbled together their inaugural board of directors—a gathering of eight experts from every corner of the autism field you can think of. They’re not playing small ball, no...

UTulsa's New Scholarship Fund: A Bold Step Forward

Pioneering Education at UTulsa Have you ever heard of a private university in the middle of America's heartland capping its undergraduate tuition? That's exactly what the University of Tulsa is doing, setting its tuition and fees at $25,000 a year come fall 2027. And they're not stopping there. With a robust $4 million boost from the Asbjornson Foundation, they're rolling...

QVC Group Readies 2026 Q3 Results, Faces Retail Shift

The Changing Faces of QVC Group Something tells me that the retail landscape’s a different beast in 2026. QVC Group, Inc. (NASDAQ:QVCG) has wired up for a crucial update we’ve all been waiting for—announcing their third quarter fiscal 2026 results. Mark your calendars for November 16th, because that’s when the SEC will get their hands on the 10-Q, and we’ll get...

QuidelOrtho Shares Plunge 14% Amid Legal Scrutiny

QuidelOrtho's Rocky Road Oh, it's been a roller coaster for QuidelOrtho's stock. Lately, it’s like holding onto a greased pole in a thunderstorm. November 9th, 2026, wasn't a friend to QDEL shareholders; the stock's down about 14%, and now some legal eagles want to know if there's more to the story. When you go poking around in the financials and spotlight that nasty...

Strathcona Resources Q3 2026: Dividends, Deals, and Growth

Digging into Strathcona's Third Quarter Strathcona Resources (TSX: SCR) is strutting its stuff again, dropping a third-quarter report that reads like a playbook for solid energy sector performance. First off, let’s talk about that dividend bump. The company decided to sprinkle some cheer with a 7% increase in its quarterly dividend, now at $0.32 per share. Not exactly...

Trimble's New Machine Control Tech Promises Big Gains

Trimble's Latest Tech: A Game-Changer? The release of Trimble's MP1087 isn't just another upgrade—it's a leap forward. The folks over at Trimble decided to do some housekeeping with their machine positioning offerings, ditching separate components for a new all-in-one device. This bad boy doesn’t just promise—it delivers up to a 15% bump in uptime, even when...

Millrose Faces Class Action Over Misleading Investors

Millrose Properties Steps Into Legal Hot Water Ah, stocks and legal squabbles—a pairing as old as Wall Street itself. Now, folks, it seems Millrose Properties, Inc. has stepped right onto the chopping block with a lawsuit knocking on their door over claims they misled investors. The suits from the DJS Law Group aren't mince words: we're talking alleged violations of the...

Lauri Thompson Joins UWSN Board: A New Era Begins

Fresh Faces and New Perspectives In a move that merges legal acumen with community heart, Lauri S. Thompson of Greenberg Traurig has stepped up as a board member for the United Way of Southern Nevada (UWSN). Now, why should we care about this? Because when someone with Thompson's clout and eight-arm octopus of involvement links up with a nonprofit, things get interesting....